Polypharmacy is now routine in older adults, and the risks rise with every added pill
When Jonathan Bledsoe noticed his urine had turned the color of freshly brewed coffee, the problem was not subtle. He had spent nearly three years taking a mood-stabilizing prescription, a cholesterol-lowering drug, and several additional medicines, only to learn that the combination was beginning to injure his liver. After his medications were changed, both his liver and kidney function returned to normal.
That bedside story captures the central danger of polypharmacy: each added drug expands the chance of interaction, side effects, duplication, and prescribing cascades that can spiral quietly for months before the damage becomes obvious. In older adults, the concern is especially sharp because drug metabolism changes with age, renal clearance often declines, and adverse effects can look like ordinary aging until they are severe enough to force a hospital visit.
A nationwide pattern mirrors that clinical reality. Among Americans older than 65, the share taking five or more medications nearly doubled from 2000 to 2020, and more than a third of older adults now take five or more drugs each day. In some geriatric practices, the burden goes far beyond that benchmark; Amanda Mixon described seeing patients taking an average of 16 medications, often prescribed by different clinicians and filled at different pharmacies.
The result is not just complexity. It is fragmentation.
How prescribing cascades create more treatment from one side effect
One of the most common traps in medicine is the prescribing cascade. A drug causes a symptom, the symptom is mistaken for a new disease, and another medication is added to treat the side effect rather than the underlying cause.
Heart failure offers a familiar example. Diuretics reduce fluid retention, but frequent urination can trigger incontinence or urgency, which may then lead to another prescription. The original problem remains treated, yet the new drug adds another layer of risk, particularly if the patient is already struggling with dizziness, dehydration, constipation, or cognitive slowing.
This is how well-intended care becomes overtreated care. Each individual prescription may be reasonable in isolation, but the cumulative effect can be harmful when no one clinician has the full medication picture. Different health systems, separate electronic records, and multiple prescribers make it easy for dangerous combinations to persist. In practice, patients and caregivers often become the only people holding the complete medication list in one place.
The issue becomes more consequential as people age because pharmacokinetics shift. Drugs can linger longer, adverse reactions can be more intense, and symptoms such as falls, memory changes, diarrhea, or constipation can be dismissed as unavoidable aging rather than medication toxicity. The line between disease and drug effect is often thin.
Deprescribing is becoming a deliberate part of safer care
The response is deprescribing, the intentional reduction or discontinuation of medications when the likely benefit no longer outweighs the harm. The concept has gained more traction over the past decade as clinicians confront the long tail of polypharmacy and the complications that accumulate with age.
Deprescribing is not the same as stopping treatment carelessly. It requires a structured review of each medication, the reason it was started, whether the original indication still exists, and whether the current dose or drug still matches the patient’s goals. For some people, the safer path is to simplify; for others, a medication that once seemed optional may still be doing important work. The clinical task is to sort the two apart.
One short but blunt reality remains: there is no magical pharmacist at the end of the line reviewing every interaction across every system.
That means the conversation has to begin in the exam room, at the bedside, or in the pharmacy, especially when a patient develops a new symptom after a recent medication change. Mixon and other clinicians encourage patients to bring up the possibility directly with primary care clinicians or specialists. The reluctance often runs in one direction only; once the subject is raised, many prescribers are open to reassessing whether every medication still earns its place.
What patients should bring to the medication review
Keeping an updated medication list is one of the simplest safety tools available. That list should include prescriptions, over-the-counter drugs, vitamins, and supplements, because interactions do not care whether a product came from a pharmacy shelf or a health store.
Digital apps, QR-code bracelets, and medication organizers can help, but a paper list tucked into a wallet or pocket is often the most reliable tool in real life. It travels with the patient when records do not. It also helps prevent the common problem of partial recall, where one clinician hears about the anticoagulant but not the supplement, or the antidepressant but not the sleep aid.
Jen Hammons, a pharmacist focused on rural health, put the principle simply: if a person cannot remember every medication, they need a list. In clinical terms, that is not a clerical detail. It is a safety intervention.
Policy changes are beginning to catch up with the clinical burden
Federal policy is starting to acknowledge how time-consuming medication review can be. New CMS guidance clarifies how clinicians and pharmacists can be paid for reviewing medication regimens and helping taper drugs when appropriate. That matters because deprescribing is labor-intensive: it involves chart review, patient counseling, monitoring for withdrawal or rebound symptoms, and coordination across multiple prescribers.
At the same time, broader political attention to psychiatric prescribing has introduced tension into the conversation. Calls to reduce overuse can help draw attention to overtreatment, but blanket messages risk oversimplifying decisions that must be individualized. A psychotropic drug, a blood pressure medication, a cholesterol agent, or a diuretic may each be justified, but only if the entire regimen still fits the patient’s current condition and tolerance.
The practical question is not how few medications a person can take. It is whether each one still has a clear role, a clear benefit, and a low enough risk profile for the patient standing in front of the clinician.
For older adults already carrying multiple prescriptions, the safest next step is often not to add another drug, but to pause and examine the list already in hand. New symptoms can be the first signal that the regimen itself has become the problem.
What to watch for when medicines stop making sense
Certain changes should trigger a medication review without delay: new confusion, unexplained fatigue, repeated falls, constipation, diarrhea, urinary problems, muscle weakness, or dark urine. These are not always medication-related, but they are common warning signs when a regimen has become too dense or when one drug is amplifying another.
Bledsoe’s case shows how quickly the consequences can move from vague discomfort to organ injury. Once the combination was changed, the laboratory abnormalities resolved. That outcome is encouraging, but it also shows how much damage can accumulate before a medication problem is recognized.
In older adults, the threshold for review should be low. A long medication list may look like comprehensive care, but the safer mark of good medicine is often the opposite: the smallest regimen that still treats the patient well.